US-listed companies
Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc.LYEL

Market cap

$383.69M

P/E ratio

Income statement Balance sheet Cash flow

	Dec 31, 2023
Net loss	-235
Stock-based compensation expense	47
Depreciation and amortization expense	20
Impairment of other investments	13
Change in fair value of success payment liabilities	-3
Net amortization and accretion on marketable securities	10
Change in fair value of success payment liabilities	-3
Non-cash lease (income) expense	2
Loss on property and equipment disposals, net	-2
Net amortization and accretion on marketable securities	10
Loss on property and equipment disposals, net	-2
Prepaid expenses, other current assets and other assets	-3
Accounts payable	1
Accrued liabilities and other current liabilities	-1
Other non-current liabilities	-0
Prepaid expenses, other current assets and other assets	-3
Accounts payable	1
Accrued liabilities and other current liabilities	-1
Other non-current liabilities	-0
Net cash used in operating activities	-164
Purchases of property and equipment	3
Purchases of marketable securities	477
Sales and maturities of marketable securities	664
Net cash provided by (used in) investing activities	184
Net cash provided by (used in) investing activities	184
Proceeds from Stock Options Exercised	0
Proceeds from Stock Plans	2
Taxes paid related to net share settlement of equity awards	0
Net cash provided by financing activities	2
Net cash provided by financing activities	2
Net increase (decrease) in cash, cash equivalents and restricted cash	22
Cash Paid For Amounts Included In Measurement Of Lease Liabilities	11
Cash Paid For Amounts Included In Measurement Of Lease Liabilities	11
Capital Expenditures Incurred but Not yet Paid	0